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A soluble IL-2 receptor (sIL-2R) is a circulating form of a membrane receptor localized on lymphoid and some cancer cells. The
biological function of sIL-2R has not been completely understood. Substantially, it seems to reﬂect T-lymphocyte activation in
diseases of diﬀerent pathology. Moreover, the soluble receptor has been considered, at least in part, responsible for unsuccessful
immunotherapy with IL-2 in cancers. Several lines of evidence indicate sIL-2R measurements to be useful in determining disease
progress and prognosis. This review summarizes current knowledge on the sIL-2R behavior in RA and solid cancers of varied
etiology.
INTRODUCTION
In 1984 Rubin and coworkers [1] reported the pres-
ence of soluble IL-2 receptors in cultured human T-cell
leukemia virus I (HTLV I)-positive T lymphocytes and
peripheral blood mononuclear cells (PBMCs) stimulated
with mitogens. Ever since then, a number of research sur-
veys have been conducted to gain a better understanding
of the substance and the functions that sIL-2Rs play in
the immune system. Twenty years after the report of the
Rubin’s group, the biological function of sIL-2R has not
yet been completely understood, though it is regarded a
marker of T-cell activation [1]. Signiﬁcantly, taking into
consideration its high (as compared to IL-2) serum con-
centration, sIL-2R measurements in serum/plasma give a
better tool for the assessment of the immune system ac-
tivity.
STRUCTURE AND FEATURES
Soluble IL-2R is part of a membrane receptor for
interleukin-2, which can be localized on the cell surface
of diﬀerent lymphoid cell lines including activated T and
NK cells, monocytes, eosinophils [2, 3, 4], and on some
tumor cells [5, 6, 7]. IL-2R ectodomains are thought to be
proteolytically cleaved from the cell surface [8, 9, 10]a n d
not produced as a result of posttranscriptional splicing
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[11]. This membrane receptor is important for cell stimu-
lation with interleukin-2 (IL-2), which is one of the most
signiﬁcant interleukins in the immune system. IL-2R ex-
ists in three diﬀerent forms: alpha (IL-2Rα, CD25, pre-
viously Tac antigen, M = 55kd), beta (IL-2Rβ, CD122,
M = 75kd), and gamma chains (IL-2Rγ, CD132, M =
64kd). A model of an IL-2 receptor is shown in Figure 1.
Being shared with other cytokine receptors, beta and
gamma chains belong to a cytokine receptor superfamily
[12],alsocalledahematopoietinreceptorfamily[13].The
beta subunit is common to IL-15 receptor [14], and the
gamma chain (known also as “common gamma chain,”
γc) toIL-4, IL-7,IL-9, andIL-15receptors [14,15,16,17].
Soluble IL-2Rβ can be found in the supernatants of stim-
ulated peripheral blood lymphocytes [18] and during in-
ﬂammatory diseases in the serum [19], whereas sIL-2Rγ
can be found in the serum [20] and in synovial ﬂuid (SF)
[21], but not in the PHA-activated human PBL cultures
[22].
The IL-2R subunits demonstrate diﬀerent binding
aﬃnities to IL-2, with the highest noted for a structure
composed of all the three subunits, in which the alpha
c h a i ni sr e q u i r e df o rt h er e c e p t o rc l u s t e r i n ga n dI L - 2s i g -
nal transduction [23]. Beta and gamma subunits show in-
termediate aﬃnities, while the alpha chain alone shows
the lowest and is not capable of signal transmitting into
cells [24]. This latter structure is not normally present on
the resting cells. Cellular expression of the alpha recep-
tor followed by its release into the circulation takes place
upon lymphocyte stimulation.
Structurally, the alpha chain is not related to the cy-
tokinereceptorfamily.Asamembranereceptoritisa251-
amino-acid-residue polypeptide, which is organized into122 Anna Maria Witkowska 2005:3 (2005)
α
β
γ
High Intermediate Low
α
β
γ
Figure 1. IL-2 membrane receptor structures with diﬀerent
aﬃnities for IL-2 binding. Receptor α alone binds IL-2 with
low aﬃnities (kd 10−8 M), not allowing signal transduction into
cells. Receptor βγ and αβγ complexes demonstrate intermediate
(kd 10−9 M) and high (kd 10−11 M) aﬃnities, respectively, en-
abling signal transduction.
twosushi(CCP/SCR)domainslinkedtoeachotherwitha
30-amino-acid chain [25], required for IL-2 binding [26].
The extracellular domains are the largest part of the re-
ceptor, which consists of 219 residues, anchored to the
cell with a small 19-residual transmembrane domain, and
a cytoplasmic domain consisting of 13 amino acids [27].
Therefore, the soluble form that comprises the extracellu-
lar part is only about 10kd lighter than the membrane-
bound receptor. Hence, the molecular weight of the solu-
ble receptor has been estimated as 35–40kd in the case of
HTLV I-positive T cells and 45–50kd for activated PBMC
[1].
BIOLOGICAL SIGNIFICANCE
Amongst the three subunits which can be released
from the cell surface, sIL-2Rα appears to possess the best
diagnostic value in a number of diseases associated with
T-cell stimulation. Substantially, membrane receptor ex-
pressionandreleasetakeplaceafterleukocytestimulation;
therefore, the presence of the alpha chain in the circula-
tion is a good measure of T-cell activation. Another ad-
vantage is its speciﬁcity to only the IL-2 receptor, whilst
the beta and gamma chains are shared with other cy-
tokinereceptors.Moreover,contrarytogamma-chainlev-
els, considerable amounts of the alpha chain can be found
in the serum [22]. The majority of the studies, therefore,
focused on sIL-2Rα, which can be measured not only in
the serum/plasma [28], but also in other bodily ﬂuids, in-
cluding synovial ﬂuid, cerebrospinal ﬂuid [29], and urine
[28].
One of the most interesting biological features of sIL-
2R is its ability to bind IL-2 with an aﬃnity similar to that
of the form present on the cell surface [30]. Such ﬁnd-
ingsaresuggestiveoftheimmunosuppressivefunctionat-
tributed to this molecule. A proposed mechanism of this
interaction is presented in Figure 2. Gooding et al [31]
investigated IL-2 bioavailability during immunotherapy
with this interleukin, as inﬂuenced by the high concentra-
tions of its soluble receptors. They found that the elevated
sIL-2R levels may lead to a decreased cellular response
to IL-2. Hence sIL-2R determination in plasma/serum
may be helpful for qualifying patients to receive IL-2 im-
munotherapy [31].
When considering the usefulness of sIL-2R for clin-
ical assessment, one must pay attention to its variability
caused by several intrinsic factors and keep this in mind
during the selection of control groups for clinical trials.
Amongst these, one is age dependence [28, 29, 30, 31, 32].
Gotoh et al [28] established that serum and urine sIL-2R
concentrationsinchildhood(age1–14years)appeartobe
2 times higher than those in adulthood (age 21–67 years).
Similar results were obtained by Sack et al [32], who mea-
sured serum sIL-2R in a group of 275 children between 3
and17yearsofage.InthisstudysIL-2Rconcentrationde-
creased along with the age of the children, but remained
higher than in the adults. High in childhood, soluble re-
ceptor concentration rises again in adulthood, resulting
in a tendency of older people to have higher levels of this
protein than young adults [33, 34].
Food intake is also one of the factors that should
be taken into consideration when studying sIL-2R lev-
els. Nutrition is of great importance to immunity and
normal immune responses. An adequate nutrient supply
provides integrity to the immune system. In this context,
the dramatic restriction of food intake must be associ-
ated with depression of the immune defense. This thesis
had been investigated in two studies, which brought forth
contradictory results. Nagata et al [35] reported the sig-
niﬁcant decrease of serum sIL-2R levels in anorexia. Un-
fortunately this survey was performed on a very small
group of anorectic subjects who were underweight or
normal. A more extensive study by Allende et al [36],
in which anorectic subjects were divided into diﬀerent
groups depending on their nutritional status, did not cor-
roborate these ﬁndings. Although several immunologi-
cal parameters were distorted in underweight patients,
the sIL-2R concentration did not diﬀer from that of the
controls. This somewhat limited evidence, and the dis-
crepanciesbetweenthestudies, showsthatmoreattention
should be focused on the sIL-2R concentration as inﬂu-
enced by the nutritional status, especially in the cancer
anorexia/cachexia syndrome.
Other factors, including time of day or night, noctur-
nal sleep and nocturnal wakefulness, do not alter serum
sIL-2R concentration [37].
AUTOIMMUNE DISEASES AND CANCERS
Autoimmune diseases and cancers were found to be
associated with an impairment in the T-cell-mediated im-
munity[38],andIL-2anditsmembranereceptorwerees-
tablished to be crucial to this process [39, 40]. At present,2005:3 (2005) Role of sIL-2R in Rheumatoid Arthritis and Cancers 123
IL-1
MHC
TCR
APC
Ag
Ag
T-cell
IL-2
IL-2
α
β
γ
Proteolytic
cleavage
α
β
γ
IL-2 IL-2
IL-2
IL-2
sIL-2Rα
(1) (2) (3) (4)
Figure 2. Immunosuppressive function of sIL-2R. (1) An internalized antigen is presented by MHC on APC to TCR. In response to
stimulationwiththeantigen,activatedTcellsproduceIL-2andexpressIL-2αreceptorontheirsurface.(2)IL-2bindstoαβγ-complex
receptoronthesurfaceoflymphocyte.Thisinteractioninducessignal transductionintocellandproliferation.(3)Proteolyticcleavage
of the IL-2Rα chain from the cell membrane. IL-2 can be bound to the remaining units of intermediate aﬃnities. (4) Soluble IL-2R
binds IL-2, preventing its interaction with membrane receptor.
IL-2 is not only thought of as a T-cell growth factor, but
also as a factor of immune self-tolerance [41].
Autoimmunization is a process that comprises of in-
tensiﬁed production of the proinﬂammatory IL-1, IL-
6, and TNF-α, and a decrease in the level of anti-
inﬂammatory IL-2. IL-6 is known for its ability to sup-
press T-cell responses. In addition to this, elevated sIL-2R
levels are at least in part responsible for the depression of
the IL-2-dependent immunity.
Table 1 summarizes results of the clinical trials which
aimed to establish serum sIL-2R concentrations in RA
and cancers. This data provides information on the sIL-
2R utility for cancer staging.
Rheumatoidarthritis
Rheumatoid arthritis (RA) is an inﬂammatory disease
leading to joint destruction. The molecular mechanism of
synovitis is associated with T-cell activation and an ele-
vated production of proinﬂammatory cytokines, metallo-
proteinases, and adhesion molecules. In human studies,
an increase of sIL-2R levels during this process has been
noted, both in serum/plasma and in synovial ﬂuid (SF)
[8, 42, 43, 44]. It was established that high levels of sIL-
2 Rf o u n di nS Fa r ep r o d u c e db ym o n o n u c l e a rc e l l s[ 45].
Cultured PBMCs from RA subjects release considerable
amounts of sIL-2R spontaneously. No correlation, how-
ever, can be seen between the membrane receptor expres-
sion and its release [46].
Detailed clinical trials show that serum sIL-2R levels
arerelatedtodiseaseduration[44]andadeclineinsIL-2R
concentration may result from joint improvement [47].
Interestingly, Klimiuk et al [48] established that serum
sIL-2R concentration is related to a histological pattern of
synovitis. Earlier studies failed to establish any correlation
between these two variables [44].
Some reports indicate relationships between sIL-2R
and laboratory markers of inﬂammation, erythrocyte
sedimentation rate (ESR) and C-reactive protein (CRP)
[44, 45, 46, 47, 48]. These ﬁndings were not conﬁrmed
by Fr¨ ode et al [49]. Other studies found positive corre-
lations between sIL-2R in serum and IL-1beta in SF [50]
orerythropoietininserum[51],andnegativecorrelations
for serum haemoglobin [51] or 1,25-dihydroxyvitamin
D3 [52], which is a known suppressor of activated T cells.
Findings from clinical trials raise a question on
whether sIL-2R concentration in serum provides a reli-
able immunological marker to assess disease activity in
RA. Earlier studies reported the possible advantages of
sIL-2R measurements for these purposes [53]. Tebib et al
[44] do, however, question the utility of sIL-2R as such
a marker, since it is not speciﬁc nor sensitive to mea-
sure disease activity in an outpatient RA population. It
also does not correlate with disease activity after pharma-
ceutical treatments with gold salts, methotrexate, or sul-
fasalazine [54, 55, 56]. Mangge et al [57], however, point
to sIL-2R determination as relevant in monitoring juve-
nile RA, because it allows the ability to ascertain disease
activityincasesinwhichcommoninﬂammatoryparame-
ters are unaltered. Suenaga et al [58] suggest sIL-2R mea-
surements to be helpful for the early diagnosis of RA in
patients with joint pain, but without symptoms of bone
or joint destruction.
Cancers
Cancer growth and development is associated with
stimulation of the immune system, including enhanced
IL-2R expression in immune cells and its shedding into
the circulation. Numerous studies have attempted to es-
tablish connections among clinical symptoms of neo-
plasm, markers of inﬂammation, and sIL-2R levels in
body ﬂuids. These reports documented the usefulness
of sIL-2R for monitoring anticancer therapy, in both
chemotherapy and surgical treatment [59].
Malignant cells of human lymphoid tumors are
thought to be the major source of serum sIL-2R. Wasik et
al [60] demonstrated in an animal study that the sIL-2R124 Anna Maria Witkowska 2005:3 (2005)
Table 1. Serum IL-2Rα concentrations in cancers and autoimmune diseases. Numbers in round brackets are numbers of study par-
ticipants. ng means not given.
Disease sIL-2R in controls sIL-2R in disease Disease/control ratio Reference
Breast cancer
428pg/mL (11) Stages I, II: 1426pg/mL (20) 3.3[ 76]
428pg/mL (11) Stages III, IV: 1184pg/mL (10) 2.8[ 76]
Renal-cell carcinoma
291U/mL (10) Stage II: 596U/mL (27) 2 [85]
291U/mL (10) Stage III: 776U/mL (8) 2.7[ 85]
291U/mL (10) Stage IV: 1310U/mL (17) 4.5[ 85]
Esophageal squamous-cell
carcinoma
1020pg/mL (103) Stage I: 1017pg/mL (11) 1 [86]
1020pg/mL (103) Stage II: 1384pg/mL (30) 1.4[ 86]
1020pg/mL (103) Stage III: 1309pg/mL (44) 1.3[ 86]
1020pg/mL (103) Stage IV: 1721pg/mL (36) 1.7[ 86]
Head and neck cancer 1036pg/mL (22) 1496pg/mL (19) 1.4[ 65]
Nasopharyngeal carcinoma
1050pg/mL (32) Stage I: 1356pg/mL (17) 1.3[ 64]
1050pg/mL (32) Stage II: 1932pg/mL (23) 1.8[ 64]
1050pg/mL (32) Stage III: 2416pg/mL (36) 2.3[ 64]
1050pg/mL (32) Stage IV: 2903pg/mL (37) 2.8[ 64]
Lung cancer
821U/mL (22) Stages IIIa-b: 880U/mL (21) 1.1[ 73]
821U/mL (22) Stage IV: 1149U/mL (18) 1.4[ 73]
507U/mL (30) Stages IIIb, IV: 906U/mL (76) 1.8[ 70]
Adenocarcinoma of lungs
54pM (18) Stages I, II: 47pM (17) 0.9[ 69]
54pM (18) Stage IIIa: 71pM (11) 1.3[ 69]
54pM (18) Stage IIIb: 87pM (10) 1.6[ 69]
54pM (18) Stage IV: 110pM (18) 2 [69]
Squamous-cell lung
carcinoma
54pM (18) Stages I, II: 73pM (9) 1.4[ 69]
54pM (18) Stage IIIa: 186pM (9) 3.4[ 69]
54pM (18) Stage IIIb: 126pM (9) 2.3[ 69]
54 pM (18) Stage IV: 86pM (5) 1.6[ 69]
Nonsmall-cell lung carcinoma
355U/mL (21) Stage Ia: 372U/mL (26) 1 [71]
355U/mL (21) Stage Ib: 409U/mL (11) 1.2[ 71]
355U/mL (21) Stage IIa: 425U/mL (3) 1.2[ 71]
355U/mL (21) Stage IIb: 391U/mL (5) 1.1[ 71]
355U/mL (21) Stage IIIa: 420U/mL (10) 1.2[ 71]
355U/mL (21) Stages IIIb, IV: 614U/mL (10) 1.7[ 71]
Ovarian cancer 58pM (20) Stages IIIb, IV: 701pM (30) 12.1[ 79]
Pancreatic cancer
648U/mL (43) Stage I: 1185U/mL (16) 1.8[ 82]
648U/mL (43) Stages II, III: 1039U/mL (60) 1.6[ 82]
648U/mL (43) Stage IV: 649U/mL (25) 1 [82]
Colorectal cancer
347U/mL (33) Stage I: 364U/mL (26) 1 [87]
347U/mL (33) Stage II: 349U/mL (45) 1 [87]
347U/mL (33) Stage IIIa: 467U/mL (26) 1.3[ 87]
347U/mL (33) Stage IIIb: 350U/mL (11) 1 [87]
347U/mL (33) Stage IV: 644U/mL (34) 1.9[ 87]
413U/mL (98) Stage I: 515U/mL (8) 1.2[ 87]
413U/mL (98) Stage II: 456U/mL (9) 1.1[ 87]
413U/mL (98) Stage III: 412U/mL (13) 1 [87]
413U/mL (98) Stage IV: 821U/mL (8) 2 [87]
Rheumatoid arthritis
355U/mL (34) 567U/mL (32) 1.6[ 88]
366U/mL (12) 687U/mL (ng) 1.9[ 89]2005:3 (2005) Role of sIL-2R in Rheumatoid Arthritis and Cancers 125
Table 1. Continued.
Disease sIL-2R in controls sIL-2R in disease Disease/control ratio Reference
Vasculitis
258pg/mL (8) Active 1279pg/mL (19) 5 [90]
258pg/mL (8) Inactive 739pg/mL (19) 2.9[ 90]
Systemic sclerosis 34pM/mL (15) 112pM/mL (42) 3.3[ 91]
68pmol/L (11) 85pmol/L (13) 1.3[ 92]
Scleroderma
1757pg/mL (12) Initial stage: 1606pg/mL (7) 1 [93]
1757pg/mL (12) Advanced stage: 3466pg/mL (16) 2 [93]
production depended on the tumor size. Several stud-
ies proved, however, that not only the lymphoid can-
cer cells express IL-2 receptors on their surface, but also
that some nonlymphoid cancer cells do, including pul-
monary carcinomas and melanoma [5, 6, 7]. Other non-
lymphoid tumors, however, such as prostatic or ovarian
carcinoma, and glioblastoma multiforme, do not seem to
be the source of sIL-2R [60].
Melanoma
Melanoma cells are capable of expressing IL-2 recep-
tors on their surface [5], and sIL-2R has been found
to correlate with disease progression [61]. In metastatic
melanoma, sIL-2R seems to reﬂect tumor burden [62].
Contrary to these ﬁndings, other researchers did not see
any connection between these two variables [63]. Ele-
vated serum sIL-2R concentration in advanced cutaneous
melanoma can provide information about worsened pa-
t i e n ts t a t u sa n dc h a n c e so fs u r v i v a l[ 62].
Headandneckcancers
Similarly to other neoplasms, sIL-2R levels in head
and neck cancers tend to be elevated [64, 65]. Lai et al
[66] established that an increase in serum sIL-2R concen-
tration in nasopharyngeal carcinoma correlates with clin-
ical staging. In other studies, high serum concentrations
at time of diagnosis were highly correlated with shorter
survival [67]. On the other hand, low levels of the soluble
receptor point to a reduced chance of metastasis develop-
ment by cancer patients within a 3-year period. Tartour
et al [67] postulated that serum sIL-2R can be employed
in head and neck cancers as an independent prognostic
markerofdistantmetastasesdevelopmentandasamarker
of the patient’s survival.
One of the advantages attributed to sIL-2R measure-
ment is its response to therapy. A study by Lai et al [66]
established that regular sIL-2R serum measurement in
about 90% of patients having sIL-2R levels elevated at di-
agnosis provided prognostic data to estimate the immune
response to radiotherapy.
Inthelatenineties of thelastcentury(1990s), Chinese
researchers investigated the advantages of photodynamic
therapy (PDT) in nasopharyngeal carcinoma and its ef-
fect on the serum IL-2R and IL-2 concentrations and NK
cell activity [68]. PDT procedure included laser superﬁ-
cial gasiﬁcation of tumor lesions and the administration
of a photosensitive agent followed by photoirradiation.
The post-PDT levels of sIL-2R were found to be signiﬁ-
cantly lower, but IL-2 levels were signiﬁcantly higher than
those before the therapy. Also, a markedly increase in NK
cell activity was noted as a result of therapy.
Lungcancer
Yano et al [7] discovered that tumor cells in pul-
monary adenocarcinoma are capable of expressing IL-2R
and releasing it into circulation. In another study they
also found that the receptor concentrations in adenocar-
cinoma and squamous-cell carcinoma were higher in the
advanced than in the early stages [69]. In the more ad-
vanced stages of small-cell carcinoma, however, sIL-2R
concentration remained unchanged.
Aleman et al [70] found high sIL-2R and other proin-
ﬂammatory cytokine concentrations as being predictive
of shorter survival among patients with advanced lung
cancers, while others gave the evidence that sIL-2R mea-
surements can be useful for metastases detection in non-
small-celllungcarcinoma[71].Theyshowedthatelevated
presurgical sIL-2R levels were indicative, with a sensitivity
of about 90%, of intrapulmonary metastases [71].
Some other practical roles attributed to sIL-2R mea-
surement are its utility in prediction of early recurrences
after tumor resection [72], as well as indication of shorter
survival in nonoperable patients treated with chemother-
apy [73].
Breastcancer
Patients with breast cancer tend to have elevated
serum sIL-2R concentrations [74, 75, 76]. No association
with the disease stage, however, has been found [74]. An
increaseinserumsIL-2Rlevelswasobservedinmetastatic
cancers when compared to nonmetastatic tumors [77].
Sharma et al [75] reported the possible immunomodu-
latory eﬀect of the IL-2 soluble receptor which suppressed
inﬁltration of blood lymphocytes into the tumor tissue.126 Anna Maria Witkowska 2005:3 (2005)
Sabbioni et al [78] noted that sIL-2R concentration
in the early breast cancer stages can be inﬂuenced by
the type of surgery performed. These researchers found
that women, who had undergone a total mastectomy,
had lower sIL-2R concentrations than those having con-
serving surgery. In opposition to surgical operations,
chemotherapy does not seem to inﬂuence serum sIL-2R
levels [76].
Ovariancancer
In advanced epithelial ovarian cancer, high serum IL-
2Rlevelshavebeenfoundtocorrelatewithanimpairment
ofT-cellresponse[79].Moreover,sIL-2Rinserumandas-
citicﬂuidtendstobehigherinadvancedepithelialovarian
cancer than in the serum and peritoneal ﬂuid of healthy
women [80].Nocorrelationwasfound,however,between
sIL-2R levels in these two bodily ﬂuids [80].
Renal-cellcarcinoma
Renal-cell carcinoma (RCC) is associated with sIL-
2R elevation in plasma, which gradually increases with
the clinical stages [31]. It has been established that RCC
subjects, having an elevated sIL-2R concentration, had a
shorter rate of survival than those with a lower concentra-
tion [31]. German researchers found that the membrane-
bound IL-2 receptor expression in patients who received a
perioperative pretreatment with IL-2 is accompanied by
sIL-2R release [81]. This ﬁnding may explain why IL-2
immunotherapy could be unsuccessful in many cases of
RCC.
Pancreaticcancer
No associations between serum IL-2R concentra-
tion and tumor grading, or lymph node involvement,
resectability, sex, and local tumor invasion in pancre-
atic adenocarcinoma were observed [82]. Interestingly,
Gansauge et al [82] noted a trend toward lower sIL-2R
concentration in patients with distant metastases, which
is in opposition to other studies, in which positive trends
or correlations have been described in various metastatic
cancers [62, 77, 83]. These researchers also found higher
sIL-2R levels in patients who are positive to anti-p53 au-
toantibodies. An earlier study established that the anti-
p53autoantibodies-positivepancreaticcancerpatientsare
signiﬁcantly less metastatic than those who are anti-p53
autoantibodies negative [84].
Colorectalcancer
According to Saito et al [83] colorectal cancer pa-
tientswhoarelivermetastasispositive,tendtohavehigher
serum sIL-2R concentrations than those without metas-
tases. Moreover, receptor concentration was found to be
independent of the presence of lymph node metastases
and not associated with the histopathological background
[83].
CONCLUSIONS
Several lines of evidence indicate sIL-2R as a non-
speciﬁc marker of T-cell activation in diseases including
RA and various cancers. Therefore its application for can-
cer staging seems to be rather questionable. A number of
surveys, however, support the utility of sIL-2R measure-
ments in monitoring disease progression and dynamics,
and early detection of recurrent disease. Moreover, by re-
ﬂecting immune response during anticancer therapy, it
oﬀers a tool for selecting an appropriate treatment strat-
egy and enables evaluation of its eﬀectiveness.
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